The Board of Directors of the Company is pleased to present the 31^st Annual Report along with the Audited Financial Statements, for
the financial year ended March 31,2026.

1. FINANCIAL RESULTS

The Standalone and Consolidated Financial Statements of
the Company for the financial year 2025-26 are prepared
in compliance with the applicable provisions of the
Companies Act, 2013 (the 'Act') including Indian Accounting
Standards specified under section 133 of the Act. The
Audited Standalone and Consolidated Financial Statements
together with the Auditors' Report thereon forms part of
this Annual Report. The Auditors' Report on Standalone and
Consolidated Financial Statement is unmodified.

2. COMPANY PERFORMANCE OVERVIEW AND
OUTLOOK AND STATE OF AFFAIRS

The Company has recorded a total income of ? 283.85
Crores for the financial year 2025-26 as against ? 300.30
Crores in 2024-25, resulting in a decrease of 5.48% in the
total income during the year under review on consolidated
basis. The Profit after Tax of the Company was decreased by
? 15.97 Crores from ? 5.04 Crores in the year 2024-25 to ?
(10.93) Crores in the year under review.

Outlook of the business has been discussed in detail in
the "Management Discussion and Analysis Report" which
forms a part of this Annual Report.

3. SHARE CAPITAL

During the year under review, the Company had allotted
2,38,847 Equity Shares of H 10 each face value upon
exercise of stock options by the eligible employees under
the Employee Stock Option Scheme 2014 and 2021.

As on March 31, 2026, the total paid up equity share
capital of the Company was H 54,24,54,550 /- consisting of
5,42,45,455 equity shares of H 10/- each, fully paid up.

As on March 31,2026, the Promoter of the Company holds
3,87,86,353 shares constituting 71.50 % of the paid- up
share capital of the Company.

4. DIVIDEND

The Board of Directors have decided not to recommend
any dividend for the financial year 2025-26, in order
to strengthen the financial position of the Company.
This decision is aligned with the Company's long-term
strategic objectives.

Pursuant to Regulation 43A of the Securities and Exchange
Board of India (Listing Obligations and Disclosure
Requirements) Regulations, 2015 (''SEBI LODR"), the Board
of Directors of the Company had formulated a Dividend
Distribution Policy. The policy is available on the Company's
website:https://www.quickheal.co.in/media/documents/
investors/Dividend-Distribution-Policy-21.pdf.

5. TRANSFER OF AMOUNT TO RESERVES

During the year under review, the Company has not
proposed to transfer any amount to the General Reserve.

6. PUBLIC DEPOSITS

During the year under review, the Company does not accept
any deposits from the public and as such, no amount on
account of principal or interest on deposits from the public
was outstanding as on the date of the balance sheet under
section 73 and 76 of the Companies Act, 2013 read with
the Companies (Acceptance of Deposits) Rules, 2014, as
amended from time to time.

7. REPORT ON PERFORMANCE OF SUBSIDIARIES

The Company has Two wholly owned subsidiaries as of
March 31, 2026. There are no associates or joint venture
companies within the meaning of Section 2(6) of the
Companies Act, 2013. There has been no material change
in the nature of the business of the subsidiaries.

The policy for determining material subsidiaries of the
Company is available on the Company's website:https://
www.quickheal.co.in/media/documents/investors/
policies/Determination-of-Material-Subsidiarv-Policv.pdf

A statement containing salient features of the financial
statements of subsidiary Companies in Form AOC-1, as
required under section 129 (3) of the Companies Act,
2013, forms a part of this Board's Report and is enclosed
as Annexure A. The Audited Financial Statements of
subsidiaries will be kept open for inspection at the
Registered Office of the Company on all working days
between 11.00 a.m. to 1:00 p.m. until the date of the
forthcoming Annual General Meeting. Further, the
Company will make available the Audited Annual
Accounts and relevant information relating to its
wholly owned subsidiary companies, to any member
open for inspection upon request submitted through
written communication.

8. MANAGEMENT DISCUSSION & ANALYSIS
REPORT (MD&A)

As per the provisions of Regulation 34(2) of the SEBI LODR,
a detailed review by the Management of the business
operations of the Company is presented under separate
section "Management Discussion and Analysis Report"
(MD&A) which forms a part of this Annual Report. MD&A
captures the Company's performance, industry trends and
other material developments.

9. CORPORATE GOVERNANCE REPORT

The Company is committed to uphold the highest standards
of Corporate Governance. It has fully complied with the
applicable provisions of Schedule V of the SEBI LODR,
relating to Corporate Governance. Quarterly Corporate
Governance Reports are regularly submitted to the stock
exchanges in accordance with regulatory requirements.

A certificate from M/s J. B. Bhave & Co., Practicing Company
Secretaries, confirming compliance with the Corporate
Governance conditions, forms part of this Annual Report.

10. BUSINESS RESPONSIBILITY AND

SUSTAINABILITY REPORT

Pursuant to Regulation 34(2)(f) of the SEBI LODR, the
Business Responsibility and Sustainability Report ("BRSR")
on initiatives taken from an environmental, social and
governance perspective, in the prescribed format is
available as a separate section of this Annual Report
and is also available on the Company's website: https://
www.quickheal.co.in/media/documents/investors/
brsr-2025-26.pdf

8 lakhs ransomware attacks were prevented in the
Financial Year 2025-26.

11. INTERGATED REPORT

The Company has provided an Integrated Annual Report
which encompasses both financial and non-financial
information to enable the Members to take well informed
decisions and have a better understanding of the
Company's long-term perspective. The Report also touches
upon aspects such as organization's strategy, governance
framework, performance and prospects of value creation
based on the six forms of capital viz. financial, service,
intellectual, human, social & relationship and natural capital.

12. RISK MANAGEMENT

The Company has established a comprehensive
risk management framework that enables effective
identification, assessment and mitigation of risk. The Board
and Audit Committee is updated quarterly on the risks of
the Company. There are no risks which in the opinion of the
Board threaten the existence of the Company. However,
risks that may pose a concern, are explained under MD&A
which forms part of this Annual Report.

The Risk Management Committee is Chaired by
Independent Director and the Chairman of the Committee
briefs the Board about significant discussions held in the
Risk Management Committee meeting.

The Risk Management Policy of the Company is
available on the Company's website at https://www.
quickheal.co.in/documents/investors/policies/Risk-
Management-Policy.pdf

13. MATERIAL CHANGES AND COMMITMENTS
AFFECTING FINANCIAL POSITION BETWEEN
THE END OF THE FINANCIAL YEAR AND DATE OF
THE REPORT

There have been no material changes and commitments
which affect the financial position of the Company that
have occurred between the end of the financial year to
which the financial statements relate and the date of
this Annual Report.

14. LISTING ON STOCK EXCHANGES

The Company's shares are listed on both the Stock
Exchanges i.e. BSE Limited and the National Stock Exchange
of India Limited.

15. COMPLIANCE WITH THE CODE OF CONDUCT

A declaration signed by the Managing Director affirming
compliance with the Company's Code of Conduct by the
Directors and Senior Management Personnel, for the
financial year 2025-26, as required under Schedule V of the
SEBI LODR forms part of this Annual Report.

16. DIRECTORS OR KEY MANAGERIAL PERSONNEL
(KMPs).

a. Composition of Board & Details of KMPs

As on March 31, 2026, the Board comprises of
Two Executive Directors and Four Non-Executive
Independent Directors. The Board is well diversified
and consists of one Independent Women Director.

Mr. Kailash Katkar, Chairman and Managing Director,
Mr. Sanjay Katkar, Joint Managing Director, Mr. Ankit
Maheshwari, Chief Financial Officer, Mr. Sarang Hari
Deshpande, Company Secretary and Mr. Vikram
Dhanani, Compliance Officer are the Key Managerial
Personnels of the Company within the meaning of
sections 2(51) and 203 of the Companies Act, 2013
read together with the Companies (Appointment and
Remuneration of Managerial Personnel) Rules, 2014
and regulation 6 (1) of SEBI LODR.

b. Appointment & Cessation during the year:

Mr. Kailash Katkar was re-appointed as Chairman
and Managing Director in the Extra-ordinary General
Meeting held on June 20, 2025, for a period of 5 Years
w.e.f. April 01,2025, to March 31,2030.

Mr. Sanjay Katkar was re-appointed as Joint Managing
Director in the Extra-ordinary General Meeting held
on June 20, 2025, for a period of 5 Years w.e.f. April 01,
2025, to March 31,2030.

The Board at its meeting held on August 07, 2025, has
appointed Ms. Amita Mirajkar as Independent Women
Director which was consequently approved by the
shareholders at the Annual General Meeting held on
September 25, 2025, for a term of 5 consecutive years

i.e. from August 07, 2025, to August 06, 2030.

The tenure of Mr. Bhushan Gokhale as an Independent
Director concluded w.e.f. August 11, 2025, pursuant
to which he ceased to be an Independent Director
of the Company.

Mr. Vishal Salvi resigned from the position of Chief
Executive Officer (CEO) w.e.f. August 31,2025.

The tenure of the second term of Ms. Apurva Joshi
as an Independent Women Director concluded w.e.f.

September 23, 2025, pursuant to which she ceased to
be an Independent Director of the Company.

c. Policy on Director's Appointment and
Remuneration

The details including the composition and terms
of reference of the Nomination and Remuneration
Committee and the meetings thereof held during
the financial year 2025-26 and the Remuneration
Policy of the Company and other matters provided
in Section 178(3) of the Act are given in the Report
on Corporate Governance section forming part of
this Annual Report.

The Policy for appointment of a new Director on the
Board is available on the Company's website: https://
quickheal.com/media/documents/investors/policies/
Nomination and Remuneration Policy.pdf

17. NUMBER OF BOARD MEETINGS

The Board of Directors met 6 (six) times during the
Financial Year 2025-26. The maximum time gap between
two meetings did not exceed the prescribed period of
one hundred and twenty days. Details relating to date of
meetings and attendance of each Directors at this meetings
are provided in Corporate Governance Report.

18. DIRECTORS' RESPONSIBILITY STATEMENT

Pursuant to Section 134(5) of the Companies Act, 2013,
the Board of Directors of the Company, to the best of their
knowledge and ability, hereby state and confirm that:

a. In preparation of the annual accounts for the financial
year ended March 31,2026, the applicable Accounting
Standards have been followed and there are no
material departures from the same;

b. The accounting policies have been selected and these
have been applied consistently and made judgements
and estimates that are reasonable and prudent, so as
to give a true and fair view of the state of affairs of the
Company at the end of the financial year March 31,
2026, and of the Loss of the Company for that period;

c. Proper and sufficient care has been taken for the
maintenance of adequate accounting records in
accordance with the provisions of the Companies
Act, 2013 for safeguarding the assets of the Company
and for preventing and detecting fraud and other
irregularities;

d. Annual accounts of the Company have been prepared
on a 'going concern' basis;

e. Internal Financial Controls have been laid down
and being followed by the Company and that such
Internal Financial Controls are adequate and were
operating effectively; and

f. Proper systems to ensure compliance with the
provisions of all applicable laws have been devised
and that such systems are adequate and were
operating effectively.

19. DECLARATION OF INDEPENDENCE BY
INDEPENDENT DIRECTORS

The Company has received declarations from each
Independent Directors under section 149(7) of the Act
and Regulation 25(8) of SEBI LODR, that he/ she fulfills the
criteria of Independence as laid down in Section 149(6) of
the Act and Regulation 16(1)(b) of SEBI LODR respectively.

The Board of Directors has evaluated the integrity,
expertise, experience and proficiency of the Independent
Directors appointed during the financial year. Based
on such evaluation, the Board is of the opinion that the
Independent Directors appointed possess the requisite
integrity, relevant expertise, rich experience and
proficiency required for effectively discharging their duties
as Independent Directors of the Company.

The Independent Directors have complied with the Code
for Independent Directors prescribed in Schedule IV to
the Act and the Code of Conduct for Directors and Senior
Management Personnel of the Company.

Based on the confirmations/disclosures received from the
Directors under Section 149(7) of the Companies Act, 2013
and regulation 25(8) of SEBI LODR on evaluation of the
relationships disclosed, the following are Non-Executive
Independent Directors:

a. Mr. Amitabha Mukhopadhyay

b. Mr. Richard Stiennon

c. Mr. Kamal Kumar Agarwal

d. Ms. Amita Mirajkar

20. BOARD EVALUATION

The Board has established a comprehensive framework for
evaluating the performance of the Board, its Committees
and of Individual Directors. An evaluation matrix
outlining the criteria for assessment has been put in place
for this purpose.

The performance evaluation of the Independent Directors
was conducted by the other members of the Board
(excluding the Director being evaluated). Additionally, a
meeting of the Independent Directors was held on March
27, 2026, to review the performance of Non-Independent
Directors and the Board as a whole. The Chairperson of
the Nomination & Remuneration Committee has updated
the other members of the Board about the outcome of the
evaluation process.

21. SUCCESSION PLANNING

The Nomination and Remuneration Committee (NRC),
in collaboration with the Board, strategically manages
leadership succession planning for both Board and Senior
Management roles, ensuring seamless transitions. The
Company prioritizes maintaining a dynamic balance
of skills and experience, continuously integrating fresh
perspectives while upholding continuity. Crucially,
promoting senior talent from within fuels the ambitions
of the broader workforce, motivating them to pursue and
achieve future leadership opportunities.

22. COMMITTEES OF THE BOARD

The Board of Directors have following Committees as on
March 31, 2026:

1. Audit Committee

2. Nomination and Remuneration Committee

3. Stakeholders Relationship Committee

4. Corporate Social Responsibility Committee

5. Risk Management Committee

The details of the composition of the Committees and
attendance of the meetings of Committees are provided in
the Corporate Governance Report.

23. SECRETARIAL AUDIT REPORT

As per the provision of Section 204 of the Companies Act,
2013 and rules made thereunder read with regulation 24A of
SEBI LODR, M/s. Ruchi Bhave, Practicing Company Secretary,
(Firm registration No. I2023MH2474600) was appointed by
the Shareholders at the 30^th Annual General Meeting, as
the Secretarial Auditor of the Company for a term of five (5)
consecutive years, commencing from Financial Year 2025¬
26 till Financial Year 2029-30. There are no qualifications/
observations / adverse remarks in the Secretarial Audit
Report for the financial year ended March 31, 2026 given
by the Secretarial Auditor. The Secretarial Auditor has not
reported any fraud during the financial year 2025-26.

The Secretarial Audit Report forms part of this Annual
Report, and is enclosed as Annexure B.

24. STATUTORY AUDITORS

M/s M S K A & Associates LLP, Chartered Accountants
(Firm Registration No. 105047W/W101187), (Previously
known as M/s M S K A & Associates), was appointed by
the Shareholders at the 29^th Annual General Meeting
held on September 06, 2024, as Statutory Auditors for
a term of five consecutive years to hold office until the
conclusion of ensuing 34^th Annual General Meeting. There
are no qualifications / observations / adverse remarks in

the Auditors Report for the financial year ended March 31,
2026, given by the Statutory Auditors.

25. INTERNAL AUDITORS

As per the provision of section 138 of the Act, the Board
has appointed P G Bhagwat LLP, as Internal Auditors of the
Company for the financial year 2025-26 to conduct the
Internal Audit of the Company.

26. COST RECORDS

Maintenance of cost records and requirement of Cost Audit
as prescribed under the provisions of Section 148(1) of the
Companies Act, 2013 are not applicable to the business
activities of the Company.

27. REMUNERATION OF DIRECTORS, KEY
MANAGERIAL PERSONNEL AND SENIOR
MANAGEMENT

As required under Section 197 (12) of the Act read with
Rule 5 of Companies (Appointment and Remuneration of
Managerial Personnel) Rules, 2014, a statement showing
median details of personnel drawing remuneration
in excess of the prescribed limit under the said rules,
are annexed as Annexure C to this Boards' Report. The
Statement containing names of top ten employees, in terms
of remuneration drawn and the particulars of employees
as required under section 197 (12) of the act read with
Rule 5(2) and 5(3) of the Companies (Appointment and
Remuneration of Managerial Personnel) Rules, 2014 will be
made available to any member on request by way of written
communication. In terms of proviso to Section 136(1) of the
Act, the Report and Accounts are being sent to the members
excluding the aforesaid Annexure. The said Annexures are
also open for inspection at the registered office up to the
date of the ensuing Annual General Meeting.

28. EMPLOYEE STOCK OPTION SCHEME

The Company has two Employee Stock Option Scheme
namely, Employees Stock Option Scheme 2014 and
Employees Stock Option Scheme 2021.

The above schemes are in line with the relevant applicable
SEBI Regulation. The Company has obtained a certificate
from the Secretarial Auditors of the Company stating
that the Schemes have been implemented in accordance
with the SBEB Regulations and the resolutions passed by
the members. The certificate is available for inspection by
members in electronic mode. The details as required to be
disclosed under the SBEB Regulations can be accessed at
https://www.quickheal.co.in/investors.

During the financial year under report, no employee has
been granted stock options, equal to or exceeding 1% of the
issued capital of the Company. The details of activities under
the scheme have been summarized in the Notes forming
part of Financial Statements and annexed as Annexure D.

29. SECRETARIAL STANDARDS

During the financial year under review, the Company has
complied with the applicable Secretarial Standards.

30. CONSERVATION OF ENERGY, TECHNOLOGY
ABSORPTION AND FOREIGN EXCHANGE
EARNINGS AND OUTGO

Particulars required to be furnished under Sub-section
(3) (m) of Section 134 of the Act read with rule 8 of the
Companies (Accounts) Rules, 2014 are as under:

a. Energy Conservation

The Company has generated 6.81% of its total power
requirement for the R&D center at Thube Park, Shivaji Nagar,
Pune, through renewable solar energy. This marks the
seventh consecutive year of renewable power generation
from the 45 kW solar plant installed at the facility.

Policy benefits:- The Company is benefiting from
lower electricity tariffs and electricity duty exemptions
under the Maharashtra IT Policy for its Head Office
and R&D centre in Pune and Nashik office.

b. Technology Absorption, Adaptation and
Innovation

The Company continues to use the latest technology for
improving the productivity and quality of its products
and services and also focuses on innovation and
protecting consumers around the world with the latest
technology. Few of the steps taken are provided below:

1. 8 ideas generated through SL have progressed to
the implementation stage, while the remaining
initiatives are being planned for execution over
the coming year.

2. Submitted research papers to leading
cybersecurity conferences, including Black Hat
USA, COCOON, BSides, and AVAR.

3. Invited to present our research at six international
conferences, including Virus Bulletin, BlueHat,
Botconf, FIRST Conference, Positive Hack
Talks, and AVAR.

4. Invited to participate in strategic cybersecurity
forums and conferences, including events
organized by I4C and the CBI Conference on
Cybercrime and Fraud (January 2026).

5. Our Advanced Persistent Threat (APT) research
has been cited and referenced by prominent
international organizations and media outlets,
including The Hacker News, Virus Bulletin, and
Recorded Future.

6. Renowned security researcher John Hammond
featured and demonstrated our research in a
dedicated video on his YouTube channel.

7. Successfully uncovered and tracked 21 global
threat campaigns and monitored the activities
of more than 300 hacktivist groups worldwide.

The expenditure incurred on Research and Development is
H 125.71 Crore.

c. Foreign Exchange earnings and outgo:

Total foreign exchange earnings and outgo for the
financial year were as follows:

31. PARTICULARS OF LOANS, GUARANTEES OR
INVESTMENTS

There are no Loans and Guarantees provided. Particulars of
Investments are provided in Notes to Accounts section of
this Annual Report.

32. RELATED PARTY TRANSACTIONS

All related party transactions undertaken during the
year were conducted in the ordinary course of business
and at arm's length. The Company did not engage in any
transactions with its related party that were materially
significant or that could have resulted in a potential
conflict of interest.

All Related Party Transactions are placed before the Audit
Committee and the Board for approval, wherever necessary.
Prior omnibus approval of the Audit Committee is obtained
for transactions which are foreseen and repetitive in nature.
[The particulars of contracts or arrangement with related
party entered during the year are given in Form AOC-2
enclosed as Annexure E].

Pursuant to the requirements of the Act and the SEBI LODR,
the Company has formulated a policy on Related Party
Transactions and the same is available on the Company's
website at https:https://www.quickheal.co.in/media/
investorrelations/corporategovernance/policy-on-related-
party-transactions-25.pdf

33. CORPORATE SOCIAL RESPONSIBILITY ('CSR')

The Company is strongly committed to contributing to the
society in which it operates. In pursuit of its Corporate Social
Responsibility (CSR) objectives, Quick Heal Foundation
has been chosen by the CSR Committee as implementing
agency and Company supports the project of chosen
CSR objective. Through these initiatives, the Company
focuses on promoting cybersecurity awareness, positively
impacting more than 82 lakh lives. The Company's

CSR Policy is available on its website athttps://www.
quickheal.co.in/media/documents/investors/policies/csr-
policy-2021.pdf.

During the year under review, the Company spent a total
of ? 1.12 Crores on CSR activities, vis-a-vis ? 1.66 Crores
i.e. above 2% of the Average Net Profit calculated as per
provisions of the Section 135 of the Companies Act, 2013.
The Company continues to remain committed towards
undertaking CSR activities for the welfare of society.

A detailed report on CSR activities of the Company in
accordance with the provisions of the Companies Act, 2013
during the financial year 2025-26 is provided as Annexure F.

34. ADEQUACY OF INTERNAL FINANCIAL
CONTROLS

The Board of Directors of your Company are responsible for
ensuring that the Internal Financial Controls ("IFC") are laid
down in the Company and that such controls are adequate
and are operating efficiently and effectively. The Company's
IFC policies are commensurate with its requirements and
are operating effectively. The IFC covered the policies and
procedures adopted by the Company for ensuring orderly
and efficient conduct of business including adherence to
the Company's policies, safeguarding of the assets of the
Company, prevention and detection of fraud and errors,
accuracy and completeness of accounting records and the
timely preparation of reliable financial information.

35. VIGIL MECHANISM/WHISTLE BLOWER POLICY

The Company has a well laid down Vigil Mechanism/
Whistle Blower Policy as required under Section 177(9) of
the Companies Act, 2013 and regulation 22 of SEBI LODR,
details of which are given in the Report on Corporate
Governance forming a part of this Annual Report. It provides
for adequate safeguard against victimization of persons
who avails this mechanism and allows direct access to the
Chairman of the Audit Committee. The Company has also
uploaded the said Whistle Blower Policy on its website at
https://www.quickheal.co.in/media/documents/investors/
policies/whistleblower-policy-&-vigil-mechanism.pdf .

36. INVESTOR EDUCATION AND PROTECTION FUND

In accordance with the provisions of Sections 124 and 125 ofthe
Act and Investor Education and Protection Fund (Accounting,
Audit, Transfer and Refund) Rules, 2016 ("IEPF Rules"),
dividends of a company which remain unpaid or unclaimed for
a period of seven years from the date of transfer to the Unpaid
Dividend Account shall be transferred by the Company to the
Investor Education and Protection Fund ("IEPF"). In terms of
the foregoing provisions of the Act, Dividend of H 1,25,730/-
and 584 number of shares were transferred to the IEPF by the
Company during the financial year 2025-26.

37. ANNUAL RETURN

Pursuant to Section 92(3) read with Section 134(3)(a) of
the Act, the Draft Annual Return as on March 31, 2026,
is available on the Company's website athttps://www.
quickheal.co.in/media/investorrelations/financials/
mgt7-2025-26.pdf

38. DISCLOSURE UNDER THE SEXUAL HARASSMENT
OF WOMEN AT WORKPLACE (PREVENTION,
PROHIBITION AND REDRESSAL) ACT, 2013

The Company has implemented a Policy on Prevention of
Sexual Harassment (POSH) at the workplace, in accordance
with the provisions of the Sexual Harassment of Women
at Workplace (Prevention, Prohibition and Redressal) Act,
2013. This policy is applicable to all employees, including
permanent, contractual, temporary staff, and trainees.
The Company has also constituted Internal Committees
(ICs) at all required locations in India to address and
resolve any complaints relating to sexual harassment.
During the financial year, no complaints were reported
under this policy.

39. MATERNITY BENEFIT ACT1961

Pursuant to Rule 8(5)(xiii) of the Companies (Accounts)
Rules, 2014, the Company confirms that it has fully
complied with the provisions of the Maternity Benefit
Act, 1961 during the financial year 2025-26. All eligible
women employees were provided with paid maternity
leave and other statutory benefits as prescribed under the
Act. The Company continues to uphold its commitment to
promoting the health, dignity, and overall well-being of
women in the workplace.

40. OTHER MATTERS

The Directors state that during the financial
year under review -

a) Neither the Managing Director nor the Joint
Managing Director of the Company have received

any remuneration or commission from any of
its subsidiaries.

b) No significant or material orders were passed by
the Regulators or Courts or Tribunals which impact
the going concern status and the Company's
operations in future.

c) The Auditors of the company have not reported any
instances of fraud against the Company by its officers
or employees as specified under Section 143(12) of
the Companies Act, 2013.

d) There is no change in the nature of the business
of the Company.

e) There is no proceeding or application filed or pending
against the Company under the Insolvency and
Bankruptcy Code, 2016.

f) There is no instance of one-time settlement with any
Bank or Financial Institution.

41. APPRECIATION

The Board places on record sincere gratitude and
appreciation for all the employees, customers, vendors,
investors, bankers, end users, dealers, distributors, business
partners and other business constituents during the year
under review. We also thank for the support received from
various government and regulatory authorities.

For and on behalf of the Board of Directors
Quick Heal Technologies Limited

Sd/- Sd/-

Kailash Katkar Sanjay Katkar

Chairman and Managing Director Joint Managing Director
(DIN: 00397191) (DIN: 00397277)

Place: Pune
Date: May 21,2026